OncoMatch/Clinical Trials/NCT05557604
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
Is NCT05557604 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Decapeptyl for prostate cancer.
Treatment: Decapeptyl — This is a prospective, open, randomized phase II trial.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage N0M0
N0M0 at staging with choline or (preferably) PSMA PET-CT
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: surgery
Previous local treatment of the prostate with surgery (radical prostatectomy or cryotherapy)
Cannot have received: radiation therapy
Previous radiotherapy to the pelvis
Cannot have received: chemotherapy
Exception: within past 5 years
Previous chemotherapy for malignancy in past 5 years
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05557604 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery, radiation therapy, chemotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage N0M0 is required.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages